Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

54 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.
Eagle GL, Zhuang J, Jenkins RE, Till KJ, Jithesh PV, Lin K, Johnson GG, Oates M, Park K, Kitteringham NR, Pettitt AR. Eagle GL, et al. Among authors: johnson gg. Mol Cell Proteomics. 2015 Apr;14(4):933-45. doi: 10.1074/mcp.M114.044479. Epub 2015 Feb 2. Mol Cell Proteomics. 2015. PMID: 25645933 Free PMC article.
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
Johnson GG, Lin K, Cox TF, Oates M, Sibson DR, Eccles R, Lloyd B, Gardiner LJ, Carr DF, Pirmohamed M, Strefford JC, Oscier DG, Gonzalez de Castro D, Else M, Catovsky D, Pettitt AR. Johnson GG, et al. Blood. 2013 Dec 19;122(26):4253-8. doi: 10.1182/blood-2013-07-516666. Epub 2013 Oct 15. Blood. 2013. PMID: 24128861 Clinical Trial.
The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.
Lin K, Lane B, Carter A, Johnson GG, Onwuazor O, Oates M, Zenz T, Stilgenbauer S, Atherton M, Douglas A, Ebrahimi B, Sherrington PD, Pettitt AR. Lin K, et al. Among authors: johnson gg. Br J Haematol. 2013 Jan;160(1):53-62. doi: 10.1111/bjh.12092. Epub 2012 Oct 30. Br J Haematol. 2013. PMID: 23110309
Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR. Lin K, et al. Among authors: johnson gg. Clin Cancer Res. 2012 Aug 1;18(15):4191-200. doi: 10.1158/1078-0432.CCR-11-2936. Epub 2012 Jun 6. Clin Cancer Res. 2012. PMID: 22675167
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P. Pettitt AR, et al. Among authors: johnson gg. J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9. J Clin Oncol. 2012. PMID: 22493413 Clinical Trial.
54 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page